Current standards and practice changing studies in genitourinary (GU) cancers-a review of studies in localized/early GU cancers.

ESMO Open · 2022 · PMC8961274 · PMID 35272133

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Subgroup analysis showed a trend towards DFS benefit in the nivolumab arm regardless of nodal status, PD-L1 expression or use of neoadjuvant chemotherapy.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.